Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Given Average Rating of "Buy" by Analysts

Shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Get Free Report) have earned an average rating of "Buy" from the ten analysts that are presently covering the stock, MarketBeat reports. Ten investment analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $27.89.

Several research firms have issued reports on CNTA. Wall Street Zen upgraded shares of Centessa Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. Oppenheimer began coverage on shares of Centessa Pharmaceuticals in a research report on Thursday, May 8th. They set an "outperform" rating and a $6.00 price target for the company. Chardan Capital began coverage on shares of Centessa Pharmaceuticals in a research report on Thursday, May 8th. They set a "buy" rating and a $30.00 price target for the company. Guggenheim restated a "buy" rating and set a $28.00 price target on shares of Centessa Pharmaceuticals in a research report on Wednesday, March 26th. Finally, Piper Sandler began coverage on shares of Centessa Pharmaceuticals in a research report on Monday, March 31st. They set an "overweight" rating and a $38.00 price target for the company.

Insider Activity at Centessa Pharmaceuticals

In related news, CEO Saurabh Saha sold 55,000 shares of the business's stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $12.71, for a total transaction of $699,050.00. Following the transaction, the chief executive officer owned 221,017 shares in the company, valued at $2,809,126.07. The trade was a 19.93% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Arjun Goyal purchased 417,646 shares of Centessa Pharmaceuticals stock in a transaction that occurred on Friday, May 16th. The shares were bought at an average price of $12.73 per share, for a total transaction of $5,316,633.58. Following the transaction, the director directly owned 462,585 shares of the company's stock, valued at $5,888,707.05. This trade represents a 929.36% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold 189,398 shares of company stock valued at $2,462,692 over the last three months. Corporate insiders own 7.09% of the company's stock.

Institutional Investors Weigh In On Centessa Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of CNTA. GF Fund Management CO. LTD. bought a new position in Centessa Pharmaceuticals in the fourth quarter worth approximately $31,000. Caitong International Asset Management Co. Ltd raised its position in Centessa Pharmaceuticals by 15,209.5% in the first quarter. Caitong International Asset Management Co. Ltd now owns 3,215 shares of the company's stock worth $46,000 after acquiring an additional 3,194 shares during the period. Osterweis Capital Management Inc. bought a new position in Centessa Pharmaceuticals in the first quarter worth approximately $47,000. Barclays PLC raised its position in Centessa Pharmaceuticals by 1,414.9% in the fourth quarter. Barclays PLC now owns 5,302 shares of the company's stock worth $89,000 after acquiring an additional 4,952 shares during the period. Finally, Bank of New York Mellon Corp bought a new position in Centessa Pharmaceuticals in the first quarter worth approximately $147,000. Hedge funds and other institutional investors own 82.01% of the company's stock.

Centessa Pharmaceuticals Stock Down 0.3%

CNTA opened at $15.08 on Wednesday. The company has a fifty day moving average price of $13.03 and a 200-day moving average price of $14.46. The firm has a market capitalization of $2.01 billion, a P/E ratio of -8.33 and a beta of 1.45. The company has a debt-to-equity ratio of 0.28, a current ratio of 14.37 and a quick ratio of 14.37. Centessa Pharmaceuticals has a one year low of $9.00 and a one year high of $19.09.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.35) by $0.15. Equities research analysts expect that Centessa Pharmaceuticals will post -1.6 earnings per share for the current fiscal year.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.